TENX — TENAX THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 34956 ·
Last close
$1.81
Market Cap
$67.74M
52W High
$19.40
52W Low
$1.31
ADV30
5,922,977
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -16,573,000 | -15,716,000 | 123,178,000 | 118,755,000 | 8,486,000 |
| Dec 2025 | 0 | — | -16,449,000 | -15,540,000 | 104,227,000 | 97,565,000 | 7,156,000 |
| Sep 2025 | 0 | — | -16,806,000 | -15,804,000 | 102,810,000 | 99,369,000 | 6,599,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,142,000
Investing CF
$0
Financing CF
$45,450,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-383,170,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-58,764,000
Pretax Income TTM
$-57,907,000
Interest Exp TTM
$0
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,385,000 | -52,599,000 | 104,227,000 | 7,156,000 | 97,071,000 | -35,800,000 |
| Dec 2024 | 0 | -19,494,000 | -17,602,000 | 96,686,000 | 4,693,000 | 91,993,000 | -14,811,000 |
| Dec 2023 | 0 | -8,234,000 | -7,711,000 | 11,685,000 | 3,587,000 | 8,098,000 | -5,904,000 |
| Dec 2022 | 0 | -11,052,643 | -11,047,895 | 3,404,709 | 1,911,968 | 1,492,741 | -11,388,571 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.50
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $1.87 · call oi: 4,731 · put oi: 1,471
Expected Move to 2026-10-16:
±$0.35
(18.74%) —
implied range
$1.52 –
$2.22
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Ltd | $68.01M | $1.08 | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $66.88M | $1.08 | — |
| GOSS | Gossamer Bio, Inc. | $66.85M | $10.94 | — |
| ATHE | ALTERITY THERAPEUTICS LTD | $66.82M | $3.67 | — |
| XBIT | XBiotech Inc. | $66.16M | $2.17 | — |
News headlines (Yahoo Finance, 1h cache)
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
2026-09-04 22:26 · Yahoo
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
2026-09-01 11:00 · Yahoo
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
2026-08-29 12:21 · Yahoo
Tenax Therapeutics’ stock crashes on Phase III trial failure
2026-08-11 11:15 · Yahoo
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
2026-08-10 15:03 · Yahoo
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-31 11:00 · Yahoo
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:05 · Yahoo
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 11:00 · Yahoo
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
2026-05-04 11:00 · Yahoo
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
2026-04-22 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.